Celebrex

ApprovedSmall molecule

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Celebrex is one of 172 small molecule programs targeting Endothelial Dysfunction. It is currently in Approved.

Indications

Total Trials

Active Trials

171

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Endothelial DysfunctionActive, not recruiting

Spinal StenosisUnknown status

Total Knee ArthroplastyCompleted

Back PainActive, not recruiting

Rheumatoid ArthritisActive, not recruiting

Ankylosing SpondylitisActive, not recruiting

Multimodal AnalgesiaCompleted

Menstrual CycleCompleted

OvulationCompleted

Endothelial DysfunctionPreclinical

Active, not recruiting

Spinal StenosisApproved

Unknown status

Total Knee ArthroplastyApproved

Completed

Back PainApproved

Active, not recruiting

Rheumatoid ArthritisApproved

Active, not recruiting

Ankylosing SpondylitisApproved

Active, not recruiting

Multimodal AnalgesiaPreclinical

Completed

Menstrual CyclePreclinical

Completed

OvulationPreclinical

Completed

Competition

Competitive Landscape

176 competitors in Rheumatoid Arthritis

#DrugCompanyPhaseTrials

Celebrex

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

2 2

Actos

Takeda

Preclinical

2 3

Celexa

AbbVie

Preclinical

1 4

Voltaren

Cataflam

Plaquenil

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

2 8

Velcade

SShilpa Grover, MD, MPH

Preclinical

2 9

Vancocin

HHikma Pharmaceuticals LLC

Preclinical

1 10

Disalcid

JJoslin Diabetes Center

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Osteoarthritis6 trials

Efficacy and Safety of SKCPT in Patients With Knee Osteoarthritis: Phase III Clinical Trial

Completed·SSK Chemicals Co., Ltd.·Phase 3·NCT05930080·278 enrolled

Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis

Completed·PPOZEN·Phase 3·NCT00664560·614 enrolled

Different Kinds of Acupuncture Treatment for Knee Osteoarthritis

Completed·ZZhejiang Chinese Medical University·N/A·NCT03563690·360 enrolled

Show 3 more trials

Celebrex Short Versus Long Therapy In Osteoarthritis Of The Knee

Completed· Pfizer logo

Pfizer·Phase 3·NCT00137410·200 enrolled

Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis

Completed·PPOZEN·Phase 3·NCT00665431·610 enrolled

Active Drug Comparative, Multi-center, phase3 Clinical Study to Evaluate the Efficacy and Safety of PG201 in Osteoarthritis Patients

Completed·PPMG Pharm Co., Ltd·Phase 3·NCT01576419·309 enrolled

Rheumatoid Arthritis2 trials

Study to Compare the Efficacy and Safety of CELBESTA® and CELEBREX® in Patients With Rheumatoid Arthritis

Completed·DDong-A ST Co., Ltd.·Phase 4·NCT02780323·119 enrolled

Phase 3 Study of Pelubiprofen Tab. & Celebrex Cap. in Rheumatoid Arthritis Patients

Completed· Daewon Pharmaceutical Co., Ltd. logo

Daewon Pharmaceutical Co., Ltd.·Phase 3·NCT01781702·120 enrolled

Papilloma2 trials

Celebrex (Celecoxib) Treatment of Laryngeal Papilloma

Terminated·—·Phase 2·NCT00592319·10 enrolled

Study of Celebrex (Celecoxib) in Patients With Recurrent Respiratory Papillomatosis

Completed·NNorthwell Health·Phase 2·NCT00571701·50 enrolled

Pain Management2 trials

Efficacy of Opioid-limiting Pain Management Protocol in Men Undergoing Urethroplasty

Completed·UUniversity of Alabama at Birmingham·Phase 4·NCT03859024·48 enrolled

Multimodal Pain Package vs. Regular Formulation for Pain Management in Ambulatory Spinal Surgery

Withdrawn·UUniversity of Miami·Phase 3·NCT05965492

Celecoxib2 trials

Pharmacokinetics Of Celecoxib Test Formulations

Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 1·NCT00925106·16 enrolled

Effect of Celecoxib on Transitional Pain After Outpatient Surgery

Withdrawn·LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's·Phase 4·NCT00664690

20 more indications

Efficacy and Safety1 trial

Efficacy and Safety of Shinbaro Capsule

Completed·GGreen Cross Corporation·Phase 3·NCT01535417·198 enrolled

Advanced1 trial

Decreasing Narcotics in Advanced Pelvic Surgery

Completed·HHartford Hospital·Phase 4·NCT02110719·138 enrolled

Total Knee Arthroplasty1 trial

Pre vs Post Block in Total Knee Arthroplasty (TKA)

Completed·UUniversity of Miami·Phase 4·NCT05974501·84 enrolled

Glioma1 trial

Safety of Fluvastatin-Celebrex Association in Low-grade and High Grade Optico-chiasmatic Gliomas

Completed·CCentre Oscar Lambret·Phase 1·NCT02115074·20 enrolled

Analgesic1 trial

MAST Trial: Multi-modal Analgesic Strategies in Trauma

Completed·TThe University of Texas Health Science Center, Houston·Phase 4·NCT03472469·1,561 enrolled

Ankylosing Spondylitis1 trial

Etanercept and Celecoxib Alone/Combined Treatment in Effectiveness and Safety of Active Ankylosing Spondylitis

Completed·SSun Yat-sen University·Phase 4·NCT01934933·150 enrolled

Ovulation1 trial

The Effect of a Non-hormonal Cox-2 Inhibitor (Celebrex) on Ovulation

Completed·OOregon Health and Science University·N/A·NCT01129245·20 enrolled

Crohn's Disease1 trial

Safety of Celecoxib in Patients With Crohn's Disease

Terminated·UUniversity of Pittsburgh·Phase 4·NCT00177866·28 enrolled

Pancreatic Cancer1 trial

Phase III Trial of Gemcitabine, Curcumin and Celebrex in Patients With Advance or Inoperable Pancreatic Cancer

Unknown status·TTel-Aviv Sourasky Medical Center·Phase 3·NCT00486460

Back pain1 trial

Celebrex vs Tramadol in the Treatment of Chronic Lower Back Pain.

Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 4·NCT00290901·754 enrolled

Endothelial Dysfunction1 trial

Effect of Acupuncture to Endothelial Dysfunction Induced by Ischemia-reperfusion Injury

Unknown status·KKyunghee University Medical Center·N/A·NCT02255006·36 enrolled

Tonsillectomy1 trial

Celecoxib for Pediatric Adenotonsillectomy

Completed·—·Phase 2·NCT00849966·282 enrolled

Spinal Stenosis1 trial

Clinical Trial of Pregabalin and COX2 in Spinal Stenosis

Unknown status·SSeoul National University Bundang Hospital·Phase 4·NCT03584074·60 enrolled

Malignant Pleural Mesothelioma1 trial

Tumor Cell Vaccines With ISCOMATRIX Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural Mesotheliomas

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT01258868·44 enrolled

Multimodal Analgesia1 trial

Efficacy of Multimodal Analgesia Following Hip Arthroscopy

Completed·WWestern University, Canada·N/A·NCT03351439·100 enrolled

Postmenopausal Women1 trial

Celecoxib Inhibition of Aromatase Expression and Inflammation in Adipose Tissue of Obese Postmenopausal Women

Completed·RRockefeller University·Phase 1·NCT01901679·10 enrolled

Hepatocellular Carcinoma1 trial

Celebrex and Metformin for Postoperative Hepatocellular Carcinoma

Unknown status·GGuangxi Medical University·Phase 3·NCT03184493·200 enrolled

Surgery1 trial

Celebrex for Pain Relief After Oral Surgery

Completed·NNational Institute of Dental and Craniofacial Research (NIDCR)·Phase 2·NCT00006299·120 enrolled

Menstrual Cycle1 trial

The Effects of a Prostaglandin Inhibitor on Ovulation and the Menstrual Cycle

Completed·OOregon Health and Science University·N/A·NCT00614406·11 enrolled

Unspecified1 trial

A Phase I Study of KLA318-2 Nanocrystal Injection

Recruiting·HHunan Kelun Pharmaceutical Co., Ltd.·Phase 1·NCT07171034·48 enrolled

Regulatory

FDA Approval Timeline[4]

Dec 31, 1998

CELEBREX

NDA NDA020998

Dec 23, 1999

CELEBREX

NDA NDA020998

Feb 17, 2000

CELEBREX

NDA NDA020998

Mar 21, 2000

CELEBREX

NDA NDA020998

Dec 1, 2000

CELEBREX

NDA NDA020998

Jul 30, 2001

CELEBREX

NDA NDA020998

Aug 15, 2001

CELEBREX

NDA NDA020998

Oct 18, 2001

CELEBREX

NDA NDA020998

Jun 7, 2002

CELEBREX

NDA NDA020998

Aug 29, 2002

CELEBREX

NDA NDA020998

Sep 16, 2002

CELEBREX

NDA NDA020998

Jan 9, 2004

CELEBREX

NDA NDA020998

Feb 9, 2005

CELEBREX

NDA NDA020998

Jul 29, 2005

CELEBREX

NDA NDA020998

Jul 29, 2005

CELEBREX

NDA NDA020998

Dec 15, 2006

CELEBREX

NDA NDA020998

Jun 1, 2007

CELEBREX

NDA NDA020998

Nov 2, 2007

CELEBREX

NDA NDA020998

Jan 14, 2008

CELEBREX

NDA NDA020998

Dec 31, 2008

CELEBREX

NDA NDA020998

Feb 4, 2011

CELEBREX

NDA NDA020998

Nov 16, 2012

CELEBREX

NDA NDA020998

Jul 29, 2013

CELEBREX

NDA NDA020998

Jul 28, 2014

CELEBREX

NDA NDA020998

May 9, 2016

CELEBREX

NDA NDA020998

May 9, 2016

CELEBREX

NDA NDA020998

Jun 28, 2018

CELEBREX

NDA NDA020998

May 3, 2019

CELEBREX

NDA NDA020998

Apr 28, 2021

CELEBREX

NDA NDA020998

Nov 21, 2024

CELEBREX

NDA NDA020998

Sources

References

[1]
ClinicalTrials.gov — 34 trial records for Celebrex. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Celebrex compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Celebrex. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA020998). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Pfizer's Upjohn has merged with Mylan to form Viatris Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Celebrex

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Osteoarthritis6 trials

Rheumatoid Arthritis2 trials

Papilloma2 trials

Pain Management2 trials

Celecoxib2 trials

Efficacy and Safety1 trial

Advanced1 trial

Total Knee Arthroplasty1 trial

Glioma1 trial

Analgesic1 trial

Ankylosing Spondylitis1 trial

Ovulation1 trial

Crohn's Disease1 trial

Pancreatic Cancer1 trial

Back pain1 trial

Endothelial Dysfunction1 trial

Tonsillectomy1 trial

Spinal Stenosis1 trial

Malignant Pleural Mesothelioma1 trial

Multimodal Analgesia1 trial

Postmenopausal Women1 trial

Hepatocellular Carcinoma1 trial

Surgery1 trial

Menstrual Cycle1 trial

Unspecified1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News